Table 1

Univariate analysis of factors associated with resolution of acute cholecystitis with ABX versus PCTs

ABXPCTP value
Total N13254
Age (years), median (IQR)57 (44–63)56 (44–66)0.95
Sex (male)54 (41%)27 (28%)0.87
Stem cell transplant26 (20%)8 (15%)0.30
Hematologic malignancy52 (39%)28 (52%)0.50
Abdominal malignancy36 (27%)17 (31%)1.00
Chemo<6 wks59 (45%)31 (57%)0.61
Abdominal radiation4 (3.0%)5 (9.3%)0.15
Nausea/vmiting57 (43%)25 (46%)0.61
Steroids18 (14%)7 (13%)0.65
ANC (1000 cells/μL), median (IQR)3.5 (2.2–6.1)6.0 (1.6–6.2)0.004
Platelets (1000/mL), median (IQR)125 (54–199)153 (63–246)0.29
Length of stay (days), median (IQR)5 (2–10)8 (6–12)0.02
ASA class
 I0 (0%)0 (0%)0.04
 II5 (3.8%)3 (5.6%)
 III92 (69.7%)27 (50%)
 IV34 (25.8%)24 (44%)
 V1 (0.8%)0 (0%)
  • Chemo<6 weeks indicates chemotherapy received less than 6 weeks to presentation.

  • ABX, antibiotics; ANC, absolute neutrophil count; ASA, American Society of Anesthesiologists; PCT, percutaneous cholecystostomy tube.